News
Stay up to date on the progress of Vesigen’s breakthrough technology
Vesigen Therapeutics
790 Memorial Drive
Suite 103
Cambridge, MA 02139
Vesigen Highlights Key in vivo and Targeted Tropism Data Advancements for Non-Viral Delivery Platform at 2024 ASGCT and ARVO Annual Meetings
New NHP data demonstrate successful functional delivery of CRISPR/Cas9 and base editing complexes with engineered ARMMs to multiple cell types ...
Vesigen to Present New Preclinical Data on Ophthalmology Applications of Engineered ARMMs at 2024 ARVO Annual Meeting
CAMBRIDGE, Mass., May 1, 2024 /Business Wire/ — Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform ...
Vesigen to Present New Preclinical Data on Engineered ARMMs Technology at 2024 ASGCT Annual Meeting
CAMBRIDGE, Mass., April 22, 2024 /Business Wire/ — Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform ...
Vesigen to Present at the 2024 Cell and Gene Meeting on the Med
CAMBRIDGE, Mass., April 3, 2024/Business Wire/ — Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform for ...
Vesigen Receives National Institutes of Health Award in Targeted Genome Editor Delivery Challenge
Vesigen proposal selected as a “Winning Solution” for programmable delivery systems for gene editing Proposal builds on recent data demonstrating ...
Vesigen Highlights Data Demonstrating Directed Tropism of Non-Viral Delivery Platform at the 30th Annual Congress of the European Society of Gene & Cell Therapy
First demonstration of directed tropism of ARMMs for cell type-specific delivery of therapeutic payloads Dose-dependent gene editing observed across multiple ...
